Market news

-- Leading multi-site OB/GYN health practice to implement FemVue® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that Minnesota Women’s Care w

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to

The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval application pathway for FemBloc, a non-surgical permanent birth control technology. Femasys Inc. (NASDAQ:FEMY) announced the regulatory milestone for its investigational contraceptive device. Office-Based Alternative To Surgical Sterilization FemBloc represents a first-of-its-kind permanent birth control option designed specifically for delivery within a standard OB/GYN office setting. During the p

Femasys has received FDA approval to use a modular premarket approval submission process for FemBloc, giving the company a defined regulatory framework as its pivotal U. S.

-- Modular PMA pathway advances FemBloc toward potential U.S. approval while Femasys builds commercial infrastructure across its reproductive health portfolio --ATLANTA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that the U.S. Food and Drug Administra

The U.S. Food and Drug Administration accepted Femasys’ modular premarket approval application for FemBloc, an experimental non-surgical permanent birth control technology.

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval -- ATLANTA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its fina

-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key intern

-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purchase agreement (the “Purchase Agreement”) for a $30 million private placement